Škrott Zdeněk Ph.D.
Journals
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
Cell Death & Disease.
2022,
13(3),
203,
ISSN: 2041-4889,
PMID: 35246527,
Cannabidiol-induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET.
Molecular Oncology.
2021,
16(7),
1541-1554,
ISSN: 1574-7891,
PMID: 34632694,
Microthermal-induced subcellular-targeted protein damage in cells on plasmonic nanosilver-modified surfaces evokes a two-phase HSP-p97/VCP response.
Nature Communications.
2021,
12(1),
713,
ISSN: 2041-1723,
PMID: 33514738,
Intellectual property
MOLECULAR COMPLEX ASSEMBLY PARTICLES COMRISING BIS-R1, R2-DITHIOCARBAMATE-METAL COMPLEX AND A LIGAND, METHOD OF PREPARATION AND USE THEREOF "DISULFIRAM II" (Mistrík)
- Published Application EP 18199181.1 under EP 3636285 (15.4.2020)
- Published Application PCT/EP2019/077222 under WO 2020/074514 (16.4.2020)
- Patent: AU 2019358428. Granted: 4.8.2022. Ownership: Palacky University Olomouc. Inventors: Mistrík Martin, Bártek Jiří, Škrott Zdeněk, Džubák Petr, Hajdúch Marián
- Patent: JP 7220932. Granted: 3.2.2023. Ownership: Palacky University Olomouc. Inventors: Mistrík Martin, Bártek Jiří, Škrott Zdeněk, Džubák Petr, Hajdúch Marián
Status: Patents pending, Available
Open positions
Project: | Cellular stress in health and disease |
---|---|
Supervisors: | Mistrík Martin Ph.D., Moudrý Pavel Ph.D., Škrott Zdeněk Ph.D. |
Available: | 3 |
Intended for: | Doctoral training |